Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

Deals > All

Total search results: 9813 | Ordered by Date (descending)
1 2 3 ... 97 98 99  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Arxspan–Bruker Corp: investment, 201903 acquisition €na of Arxspan LLC by Bruker Corp 2019-03-14
Rocket Pharmaceuticals–MolMed: gene therapy, 201903– collab expansion developm + manufacture of lentiviral vectos by MolMed for three new indications 2019-03-13
Biogen–Fujifilm: biologics contract manfuacturing, 201903– supply manufacturing of biologicals for Biogen incl Tysabri 2019-03-12
Biogen–Fujifilm: investment, 201903– acquisition up to $890m in cash of Biogen’s Biologics Manufacturing Site in Hillerød Denmark 2019-03-12
Oxford BioMedica–Microsoft: bioinformatics, 201903–202102 collab r+d using MS Azure cloud + machine learing to optimise gene therapy vectors 2019-03-12
AstraZeneca–Seres Therapeutics: microbiomics, 201903–202202 collab research 3y $20m + research funding for microbiomics to support I-O therapies 2019-03-11
Snipr Biome–Life Sciences Partners: investment, 201903 financing round Series A totalling $50m incl co-lead investor LSP 2019-03-11
Snipr Biome–Lundbeck: investment, 201903 financing round Series A totalling $50m incl existing + co-lead investor Lundbeckfonden Emerge 2019-03-11
Snipr Biome–North-East Family Office: investment, 201903 financing round Series A totalling $50m incl co-investor North-East Family Office 2019-03-11
Snipr Biome–SEVERAL: investment, 201903 financing round Series A $50m co-led by Lundbeckfonden Emerge + Life Sciences Partners 2019-03-11
Snipr Biome–Wellington Partners: investment, 201903 financing round Series A totalling $50m incl co-investor Wellington Partners 2019-03-11
Qiagen–Tecan: lab automation, 201903– collab direct supply of Tecan Fluent workstation for sample to labs using QuantiFeron-TB Gold Plus test 2019-03-08
Gilde Investment–SEVERAL: investment, 201903 final close €200m Gilde Healthcare Service III fund incl PGGM/PF Zorg en Welzijn + Rabo Corp Investments 2019-03-07
SOM Biotech–SEVERAL: investment, 201903 financing round €7m led by European family holding 2019-03-07
BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m 2019-03-05
Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB 2019-03-05
abcr GmbH–Enzymicals: enzymes, 201903– collab distribution expansion ww sale of all catalogue products of Enzymcials by acbr 2019-03-04
Ascendis Pharma–SEVERAL: investment, 201903– public offering $400m+$60m ADSs 2019-03-04
Nightstar Therapeutics–Biogen: investment, 201903– acquisition $877m in cash at $25.5/share ANNOUNCED 2019-03-04
Anaeropharma Science–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility 2019-03-01
Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum 2019-02-28
Sarepta Therapeutics–Centogene: molecular diagnostics, 201902–202002 collab service identifying DMD patients in MENA region by Centogene 2019-02-28
CN Innovations–MIT: organ-on-a-chip technology, 201902– license excl for organ-on-a-chip with human tissues fomr up to 10 organs for CN Bio 2019-02-27
Genfit–SEVERAL: investment, 201902– private placement of ordinary shares in Europe + outside North America 2019-02-27
Genfit–SEVERAL: investment, 201902– US IPO of ADSs FILED 2019-02-27
MeiraGTx–683 Capital Management: investment, 201902 private placement totalling $80m incl co-investor 683 Capital Management 2019-02-27
MeiraGTx–JnJ: investment, 201902 private placement totalling $80m incl $40m from lead investor JJDC Inc 2019-02-27
MeiraGTx–Orbimed: investment, 201902 private placement totalling $80m incl co-investor Orbimed Advisors 2019-02-27
MeiraGTx–Perceptive Advisors: investment, 201902 private placement totalling $80m incl co-investor Perceptive Advisors 2019-02-27
MeiraGTx–SEVERAL: investment, 201902 private placement $80m with 5.8m ordinary shares at $13.8/share led by JJDC Inc 2019-02-27
Versum Materials–Merck (DE): investment, 201902– unsolicited all-cash offer at $48/share by Merck 2019-02-27
Anaveon–Novartis: investment, 201902 financing round Series A totalling CHF35m incl co-investor Novartis Venture Fund 2019-02-26
Anaveon–SEVERAL: investment, 201902 financing round Series A CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Anaveon–Wellcome Trust: investment, 201902 financing round Series A totalling CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Hookipa–Invus Group: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Invus 2019-02-26
Hookipa–Redmile Group: investment, 201902 financing round Series D totalling €33.2m incl new + lead investor Redmile Group 2019-02-26
Hookipa–Samsara BioCapital: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Samsara BioCapital 2019-02-26
Hookipa–SEVERAL: investment, 201902 financing round Series D €33.2m ($37.4m) led by Redmile Group + incl Invus + Samsara Capital et al. 2019-02-26
General Electric–Danaher: investment, 201902– acquisition $21.4b in cash of biopharma business of GE Life Sciences ANNOUNCED 2019-02-25
Roche–Citigroup: financial services, 201902 supply Citi financial advisor to Roche with regard to acquisition of Spark by Roche 2019-02-25
Roche–Davis Polk & Wardwell: legal services, 201902 supply service legal advisor to Roche w regard acquisition of Spark Therapeutics 2019-02-25
Spark Therapeutics–Centerview Partners: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Cowen: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Goodwin Procter: legal services, 201902 supply legal counsel to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Roche: investment, 201902– acquisition $4.3b cash tender offer for all shares at $114.5/share ANNOUNCED 2019-02-25
Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures 2019-02-21
Aidence–ABP (NL): investment, 201902 financing round Series A totalling €10m incl lead investor Inkef Capital 2019-02-20
Aidence–Rabo Ventures: investment, 201902 financing round Series A totalling €10m incl co-investor Rabo Ventures 2019-02-20
Aidence–SEVERAL: investment, 201902 financing round Series A €10m led by Inkef Capital + co-investor Rabo Ventures et al 2019-02-20
Alchemist Accelerator–BASF: investment, 201902 BASF Venture Capital invests $2m + becomes Limited Partner 2019-02-20
BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund 2019-02-20
BiomX–MacDougall Biomedical Communications: public relations, 201902 service existent by MacDougall 2019-02-20
BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al 2019-02-20
BPCE–Yucatan: public relations, 201902 service existent media relations for Seventure Parnters in France by Agence Yucatan 2019-02-20
Calypso Biotech–ABP (NL): investment, 201902 financing round Series A totallling €20m incl co-lead investor Inkef Capital 2019-02-20
Calypso Biotech–Gilde Investment: investment, 201902 financing round Series A totallling €20m incl co-lead investor Gilde Healthcare 2019-02-20
Calypso Biotech–JnJ: investment, 201902 financing round Series A totallling €20m incl co-investor JnJ Innovation JJDC 2019-02-20
Calypso Biotech–Merck (DE): investment, 201902 financing round Series A totallling €20m incl co- + founding investor M Ventures 2019-02-20
Calypso Biotech–SEVERAL: investment, 201902 financing round Series A €20m co-led by Gilde Healthcare + Inkef Capital 2019-02-20
Evotec–Helmholtz: antibiotics, 201902– collab development with initial focus on cystobactamids with Helmholtz HZI Braunschweig 2019-02-20
CRISPR Therapeutics–StrideBio: AAV vectors, 201902– collab expansion €na of developm + license option usingStrideBio’s vectors for CRISPR therapies 2019-02-19
Gain Therapeutics–Fondazione Centenario BancaStato: investment, 201902 financing round Series A totalling €2.5m incl €400k from TiVenture SA 2019-02-19
Gain Therapeutics–Helsinn: investment, 201902 financing round Series A totalling €2.5m incl €1m from new investor Helsinn Investment Fund SA 2019-02-19
Gain Therapeutics–SEVERAL: investment, 201902 financing round Series A €2.5m from VitaTech + Helsinn Investment Fund + TiVenture 2019-02-19
Gain Therapeutics–VitaTech: investment, 201902 financing round Series A totalling €2.5m incl €1.1m from new investor VitaTech SA 2019-02-19
Qiagen–Curetis: bioinformatics, 201902– license excl to use ARESdb for general bioinformatics research offerings + services for AMR research 2019-02-18
S-Biomedic–DSM: investment, 201902 financing round Series A 2nd closing totalling €2m incl new investor DSM Venturing 2019-02-18
S-Biomedic–SEVERAL: investment, 201902 financing round Series A 2nd closing €2m from new investor DSM Venturing + existing investor investiere.ch 2019-02-18
S-Biomedic–Verve Capital Partners: investment, 201902 financing round Series A 2nd closing totalling €2m incl existing investor investiere.ch 2019-02-18
Sygnature Discovery–BioStrata: public relations, 201902 service existent by BioStrata 2019-02-15
Arvelle Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling $180m incl investor Andera Partners 2019-02-14
Arvelle Therapeutics–BRV Capital: investment, 201902 financing round Series A totalling $180m incl investor BRV Capital Management 2019-02-14
Arvelle Therapeutics–H.I.G. Capital: investment, 201902 financing round Series A totalling $180m incl investor H.I.G. BioHealth Partners 2019-02-14
Arvelle Therapeutics–Life Sciences Partners: investment, 201902 financing round Series A totalling $180m incl lead investor LSP 2019-02-14
Arvelle Therapeutics–NovaQuest Capital: investment, 201902 financing round Series A totalling $180m incl investor NovaQuest Capital Management 2019-02-14
Arvelle Therapeutics–Sam Brown: public relations, 201902 service existent by Sam Brown Inc 2019-02-14
Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate 2019-02-14
Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals 2019-02-14
Novartis–AbCellera: therapeutic antibodies, 201902– collab discovery use of AbCellera technology + screening for up to ten targets 2019-02-14
Plasmion–Bavaria (govt): investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–High-Tech Gründerfonds: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–PERSON: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–SEVERAL: investment, 201902 financing round almost €1m from HTGF + BayBG + business angel 2019-02-14
CiToxLab–Charles River: investment, 201902– acquisition $448m in cash BINDING OFFER SIGNED 2019-02-13
Boehringer–IBM: blockchain technology, 201902– collab to integrate blockchain technology into clinical trials of BI Canada + IBM Canada 2019-02-12
Grey Wolf Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Canaan Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Consilium: public relations, 201902 service existent by CSC 2019-02-11
Grey Wolf Therapeutics–SEVERAL: investment, 201902 financing round Series A £10m with Andera Partners + Canaan 2019-02-11
Symrise–SEVERAL: investment, 201902 capital increase €400m with 5.614m new shares at €71.25/share to fund acquisition of ADF/IDF 2019-02-08
Galapagos–Evotec: antifibrotic, 201902– collab + ww commercial rights for Galapagos to small-molecule programme for fibrotic diseases 2019-02-07
Invisible Sentinel–Mérieux: investment, 201902 acquisition $75m in cash by bioMérieux 2019-02-07
Pathios Therapeutics–Sygnature Discovery: drug discovery services, 201902– collab service discovery for GPCR target in autoimmune diseases + cancer 2019-02-07
Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research 2019-02-06
Bruker Corp–Genedata: drug screening software, 201902 collab product integration Bruker new Ready-to-Run partner 2019-02-05
Lilly–ProteoNic: rec protein production technology, 201902– license non-excl €na to use 2G UNic technology to boost rec protein production 2019-02-05
1 2 3 ... 97 98 99  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top